arrow
S

Stacy E. Croteau

boston bleeding disorders center
H指数:24
被引数:2,199

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lack of Inhibitor Development in Previously Treated People With Haemophilia Switching Factor Products—Final Results of Athn 2: Factor Switching Study

先前接受过治疗的血友病患者转换因子产品时缺乏抑制剂发展——Athen 2:因子转换研究的最终结果

2026-09-150
OAAI
Assessment of documentation & reporting methods for annual bleeding rate in hemophilia clinical trials: Communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders

评估血友病临床试验中年度出血率的文档记录与报告方法:ISTH SSC 关于 FVIII、FIX 和罕见凝血障碍分委员会的通讯

2026-09-090
PRE
Recommendations for harmonizing definition, recording and reporting of the annual bleeding rate (ABR) in hemophilia: Communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders."

关于协调血友病年度出血率(ABR)定义、记录和报告的建议:来自ISTH SSC凝血因子VIII、凝血因子IX和罕见凝血障碍分委员会的通讯。

2026-09-090
PRE
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

艾美珠单抗(Emicizumab)在参与ATHN 7血友病自然史研究(Haemophilia Natural History Study)的A型血友病患者中的安全性与有效性。

2025-11-110
OAAI
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
2022-12-1423
OAAI
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain
2022-03-085
OA